

HE Dr. George Norton
Minister of Public Health
Ministry of Public Health
Brickdam, Stabroek
Georgetown
Republic of Guyana

25 November 2016

Decision Letter: Request for 2017 Renewal of Gavi support for Inactivated Polio Vaccine

Your Excellency,

I am writing in relation to Guyana's request for renewal of the New Vaccine Support (NVS) for Inactivated Polio Vaccine that was reviewed by Gavi Managing Directors on 18 October 2016.

Following the recommendations made by the Managing Directors, I am pleased to inform you that Gavi has **approved** Guyana's request to renew Gavi support for Inactivated Polio Vaccine for 2017, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

- Appendix A: Guyana Support for Inactivated Polio Vaccine (IPV)
- Appendix B: Guyana Support for Immunisation supplies
- Appendix C: Recommendations of the Managing Directors Review
- Appendix C: Final 2016 Joint Appraisal Report

Please do not hesitate to contact my colleague Mr L. Homero Hernandez, Senior Country Manager for Guyana, at hhernandez@gavi.org if you have any questions or concerns.

Sincerely yours,



Hind Khatib-Othman
Managing Director, Country Programmes

cc: Minister of Finance
Director of Planning, Ministry of Health
EPI Manager, Ministry of Health
WHO Country Representative
WHO AMRO/PAHO
WHO HQ
UNICEF Country Representative
UNICEF Regional Office
UNICEF Programme Division

Decision Letter - Guyana Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

| | | | |
|--|------------------|-------------|--------------------------|
| 1. Country: Guyana | | | |
| 2. Grant number: 17-GUY-25b-X / 15-GUY-08h-Y | | | |
| 3. Date of Decision Letter: 25/11/2016 | | | |
| 4. Date of the Partnership Framework Agreement: 5/02/2015 | | | |
| 5. Programme title: New Vaccine Support (NVS), IPV routine | | | |
| 6. Vaccine type: Inactivated Polio Vaccine (IPV) | | | |
| 7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID | | | |
| 8. Programme duration²: 2015 - 2018 | | | |
| 9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i> | | | |
| | 2015-2016 | 2017 | Total³ |
| Programme Budget (US\$) | 77,000 | 36,000 | 113,000 |
| 10. Vaccine introduction grant: US\$ 100,000 disbursed in September 2015 | | | |
| 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ | | | |
| Type of supplies to be purchased with Gavi funds in each year | | | 2017 |
| Number of IPV vaccines doses | | | 18,300 |
| Annual Amounts (US\$) | | | US\$36,000 |
| 12. Procurement agency: PAHO | | | |
| 13. Self-procurement: Not applicable | | | |
| 14. Co-financing obligations: Gavi's usual co-financing requirements do not apply to IPV. However, Guyana is encouraged to contribute to vaccine and/or supply costs for IPV. | | | |
| 15. Operational support for campaigns: Not applicable | | | |

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ Importe total aprobado por Gavi para el periodo 2015-2017.

⁴ This is the amount that Gavi has approved.

16. Additional reporting requirements:

| Reports and other information | Due dates |
|---|-------------------------------|
| To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | May |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Secretariat |

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual product presentation and number of doses shipped may differ from the amounts specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
25 November 2016

Decision Letter - Guyana Support for Injection safety devices

This Decision Letter sets out the Programme Terms of a Programme.

| | | |
|--|-------------|--------------------------|
| 1. Country: Guyana | | |
| 2. Grant number: 17-GUY-32a-X | | |
| 3. Date of Decision Letter: 25/11/2016 | | |
| 4. Date of the Partnership Framework Agreement: 5/02/2015 | | |
| 5. Programme title: Injection safety devices ⁵ | | |
| 6. Programme duration⁶: 2017 | | |
| 7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable) | | |
| | 2017 | Total⁷ |
| Programme Budget (US\$) | 1,000 | 1,000 |
| 8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁸ | | |
| TOTAL injection safety devices to be purchased with Gavi funds in each year | | 2017 |
| Number of AD syringes | | 17,200 |
| Number of safety boxes | | 200 |
| Annual Amounts for injection safety devices for all Gavi vaccines (US\$) | | US\$ 1,000 |
| Injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u> | | |
| New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID,Routine | | 2017 |
| Number of AD syringes | | 17,200 |
| Number of safety boxes | | 200 |
| Annual Amounts for injection safety devices for Vaccine (US\$) | | US\$ 1,000 |
| 9. Procurement agency: PAHO. | | |
| 10. Self-procurement: Not applicable | | |

⁵ This does not include vaccines.

⁶ This is the entire duration of the Programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁸ This is the amount that Gavi has approved.

11. Co-financing obligations:

Co-financing requirements are listed in the relevant vaccine Decision Letter.

Signed by,

Hind H. Khatib

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
25 November 2016

Recommendations of the Managing Directors Review

The MDs, following their deliberations:

- Recommended to the CEO:

| Programme | Recommendation | Period | Indicative amount to be paid by Gavi |
|-----------|----------------|--------|--------------------------------------|
| NVS – IPV | Renewal | 2017 | US\$ 36,000 |

- Noted the following prioritised country needs, as identified in the Joint Appraisal:

| Prioritized needs and strategic actions | Associated timeline for completing the actions | Does this require technical assistance?* (yes/no) If yes, indicate type of assistance needed |
|---|--|---|
| Capacity building at all levels as it relates to public health administration (supervision) and management of programme (e.g., target setting and vaccine stock management) | 2017 | yes |
| Strengthening of surveillance for VPD (e.g. Technical support for monitoring and evaluation of the implementation of HPV) | 2017 | Yes |
| Health system planning and management (e.g., to improve human resources training/distribution/incentives, transportation, supply distribution [gas and other]) | 2017 | Yes |
| Advocacy and communication for strengthening of the EPI programme | 2017 | Yes |